Abstract
Purpose
The sedating effect of first generation H1-antihistamines has been associated with their ability to penetrate the blood-brain barrier (BBB) and lack of efflux by P-glycoprotein (Pgp). Second generation H1-antihistamines are relatively free of sedation and their limited brain penetration has been suggested to arise from Pgp-mediated efflux. The objective of this work was to evaluate the role of Pgp in brain penetration of first and second generation antihistamines.
Methods
Potential of antihistamines to be Pgp substrates was tested in vitro using Madin Darby canine kidney cells transfected with human Pgp. The role of Pgp in limiting brain penetration of antihistamines was tested by using the in situ brain perfusion technique.
Results
Majority of antihistamines were Pgp substrates in vitro. Following in situ brain perfusion, the first generation antihistamines substantially penetrated into rat brain independently from Pgp function. The second generation antihistamines terfenadine and loratadine, achieved substantial brain penetration, which was further enhanced by Pgp inhibition by cyclosporin A (CSA). In contrast, fexofenadine and cetirizine, penetrated brain poorly regardless of CSA administration.
Conclusions
Antihistamines greatly differ in their ability to cross the BBB as well as in the role of Pgp in limiting their transport into the CNS in vivo.
Similar content being viewed by others
Abbreviations
- BBB:
-
blood-brain barrier
- CSA:
-
cyclosporin A
- CNS:
-
central nervous system
- Kin :
-
unidirectional transfer constant
- Papp:
-
apparent permeability coefficient
References
F. Estelle and R. Simons. Advances in H1-antihistamines. N. Engl. J. Med. 351:2203–2217 (2004).
I. Hindmarch, S. Johnson, R. Meadows, T. Kirkpatrick and Z. Shamsi. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and wheal and flare. Curr. Med. Res. Opin. 17:241–255 (2001).
H. Timmerman. Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy 55 (Suppl. 60):5–10 (2000).
A. M. ter Laak, G. J. Bijloo, M. J. E. Fisher, K. G. M. Donne-Op, P. A. Carrupt, B. Testa, and H. Timmerman. Serum protein binding of histamine H1-antagonists: a comparative study on the serum protein binding of a sedating (3H-mepyramine) and a non-sedating H1-antagonist (3H-loratadine). Eur. J. Pharm. Sci. 4:307–319 (1996).
A. M. ter Laak, K. G. M. Donne-Op, A. Bast, and H. Timmerman. Is there a difference in the affinity of histamine H1-receptors agonists for CNS and peripheral receptors? Eur. J. Pharm. Sci. 232:199–205 (1993).
A. M. ter Laak, R. S. Tsai, K. G. M. Donne-Op, and G. M. Kelder. Lipophilicity and hydrogen-bonding capacity of H1-antihistaminergic agents in relation to their central sedative side-effects. Eur. J. Pharm. Sci. 2:373–384 (1994).
M. Chishty, A. Reichel, J. Siva, N. J. Abbot, and D. J. Begley. Affinity for the P-glycoprotein efflux pump at the blood brain barrier may explain the lack of CNS side-effects of modern antihistamines. J. Drug Target. 9:223–228 (2001).
C. Chen, E. Hanson, J. W. Watson, and J. S. Lee. P-Glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab. Dispos. 31:312–318 (2003).
A. H. Schinkel. P-glycoprotein: a gatekeeper in the blood-brain barrier. Adv. Drug Del. Rev. 36:179–194 (1999).
A. H. Schinkel, J. J. M. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter L, C. A. A. M. Mol, M. A. van der Valk, E. C. Robanaus-Maandag, H. P. J. te Riele, A. J. M. Berns, and P. Borst. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502 (1994).
H. Sun, H. Dai, N. Shaik, and W. F. Elmquist. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55:83–105 (2003).
H. A. Volk, and W. Loscher. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 128:1358–1368 (2005).
N. Ishiguro, T. Nozawa, A. Tsujihata, A. Saito, W. Kishimoto, K. Yokoyama, T. Yosumoto, K. Sakai, T. Igarashi, and I. Tamai. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab. Dispos. 32:519–524 (2004).
J. W. Polli, T. M. Baughman, J. E. Humphreys, K. H. Jordan, A. L. Mote, J. A. Salisbury, T. K. Tippin, and C. J. Serabjit-Singh. P-glycoprotein influences the brain concentration of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J. Pharm. Sci. 92:2082–2089 (2003).
M. Cvetkovic, B. Leake, M. F. Fromm, G. R. Wilkinson, and R. B. Kim. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866–871 (1999).
K. M. Mahar Doan, S. A. Wring, L. J. Shampine, K. H. Jordan, J. P. Bishop, J. Kratz, E. Yang, C. J. Serabijit-Singh, K. K. Adkison, and J. W. Polli. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72:92–98 (2004).
F. Bonifazi, L. Provinciali, L. Antonicelli, M. B. Bilo, S. Pucci, M. Signorino, B. Franciolino, B. Censori, P. Pagelli, and A. Iudice. Comparative study of terfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. J. Investig. Allergol. Clin. Immunol. 5:40–46 (1995).
A. Shamsi and I. Hindmarch. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum. Psychopharmacol. 15: Suppl. 1: S3–S30 (2000).
I. Hindmarch, Z. Shamsi, and S. Kimber. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin. Exp. Allergy 32: 133–139 (2002).
M. Tashiro, Y. Sakurada, K. Iwabuchi, H. Mochizuki, M. Kato, M. Aoki, Y. Funaki, M. Itoh, R. Iwata, D. F. Wong, and K. Yanai. Central effects of fexofenadine and cetirizine; measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J. Clin. Pharmacol. 44:890–900 (2004).
J. W. Polli, S. A. Wring, J. E. Humphreys, L. Huang, J. B. Morgan, L. O. Webster, and C. J. Serabjit-Singh. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:620–628 (2001).
K. M. Mahar Doan, J. E. Humphreys, L. O. Webster, S. A. Wring, L. J. Shampine, C. J. Serabjit-Singh, K. K. Adkison, and J. W. Polli. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303:1029–1037 (2002).
Q. Wang, J. D. Rager, K. Weinstein, P. S. Kardos, G. L. Dobson, J. Li, and I. J. Hidalgo. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int. J. Pharm. 288:349–359 (2005).
H. Tahara, H. Kusuhara, E. Fuse, and Y. Sugiyama. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos. 33:963–968 (2005).
A. Doran, R. S. Obach, B. J. Smith, N. A. Hosea, S. Becker, E. Callegari, C. Chen, X. Chen, E. Choo, J. Cianfrogna, L. M. Cox, J. P. Gibbs, M. A. Gibbs, H. Hatch, C. E. C. A. Hop, I. N. Kasman, J. LaPerle, J. Liu, X. Liu, M. Logman, D. Maclin, F. M. Nedza, F. Nelson, E. Olson, S. Rahematpura, D. Raunig, S. Rogers, K. Schmidt, D. K. Spracklin, M. Szewc, M. Troutman, E. Tseng, M. Tu, J. W. Van Deusen, K. Venkatakrishnan, G. Walens, E. Q. Wang, D. Wong, A. S. Yasgar, and C. Zhang. The impact of P-glucoprotein on the disposition of drugs targeted for indications in the central nervous system: evaluation using MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33:165–174 (2005).
S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J. M. Schermann. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64:3296–3301 (2004).
N. N. Salama, E. J. Kelly, T. Bui, and R. J. Ho. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J. Pharm. Sci. 94:1216–1225 (2005).
Y. Takasato, S. I. Rapaport, and Q. R. Smith. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247:H484–H493 (1984).
Q. R. Smith. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm. Biotechnol. 8:285–307 (1996).
J. A. Street, B. A. Hemsworth, A. G. Roach, and M.D. Day. Tissue levels of several radio labeled beta-adrenoceptor antagonists after intravenous administration in rats. Arch. Int. Pharmacodyn. Ther. 237:180–190 (1979).
B. V. Zlokovic, D. J. Begley, B. M. Djuricic, and D. M. Mitrovic. Measurement of solute transport across the blood-brain barrier in the perfused guinea pig brain: method and application to N-methyl-alpha-aminoisobutyric acid. J. Neurochem. 46:1444–1451 (1986).
J. E. Preston, H. Al-Sarraf, and M. B. Segal. Permeability of the developing blood-brain barrier to 14C-mannitol using the rat in situ brain perfusion technique. Brain Res. Dev. Brain Res. 87:69–76 (1995).
K. A. Youdim, M. Z. Qaiser, D. J. Begley, C. Rice-Evans, and N. J. Abbott. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 36:592–604 (2004).
M. J. Mattila, and I. Paakkari. Variations among non-sedating antihistamines: are there real differences? Eur. J. Clin. Pharmacol. 55:85–93 (1999).
D. E. Clark. Prediction of intestinal absorption and blood-brain barrier penetration by computational methods. Comb. Chem. High Throughput Screen. 4:477–496 (2001).
H. Mizuuchi, T. Katsura, H. Saito, Y. Hashimoto, and K. I. Inui. Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system. J. Pharmacol. Exp. Ther. 290:388–392 (1999).
H. Mizuuchi, T. Katsura, K. Ashida, Y. Hashimoto, and K. I. Inui. Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 278:G563–G569 (2000).
K. K. Kandimalla, and M. D. Donovan. Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J. Pharm. Sci. 94:613–624 (2005).
S. Lundquist, M. Renftel, J. Brillault, L. Fenart, R. Cecchelli, and M. P. Dehouck. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm. Res. 19:976–981 (2002).
S. G. Summerfield, A. J. Stevens, L. Cutler, M. C. Osuna, B. Hammond, S. P. Tang, A. Hersey, D. Spalding, and P. Jeffrey. Improving the in vitro prediction of in vivo CNS penetration: integrating permeability, Pgp efflux and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 316:1282–1290 (2006).
X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Backer, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, N. Hosea, J. Liu, F. R. nelson, M. A. Szewc, and J. V. Deusen. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther. 313:1254–1262 (2005).
K. Yanai, J. H. Ryu, T. Watanabe, R. Iwata, T. Ido, Y. Sawai, K. Ito, and M. Itoh. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br. J. Pharmacol. 116:1649–1655 (1995).
J. C. Verster, and E. R. Volkerts. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann. Allergy Asthma Immunol. 92:294–303 (2004).
R. D. Mann, L. G. Pearce, N. Dunn, and S. Shakir. Sedation with “non-sedating” antihistamines: four prescription-event monitoring studies in general practice. BMJ 320:1184–1187 (2000).
Acknowledgment
The authors are grateful to Hilltop Labs (Scottdale, PA, USA) for their assistance in this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Obradovic, T., Dobson, G.G., Shingaki, T. et al. Assessment of the First and Second Generation Antihistamines Brain Penetration and Role of P-Glycoprotein. Pharm Res 24, 318–327 (2007). https://doi.org/10.1007/s11095-006-9149-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-006-9149-4